Obsessive-compulsive and perseverative behaviors in Huntington's disease.

Huntington’s Disease Neuropsychiatry Obsessive-Compulsive Behavior Perseverative Behavior

Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
26 Feb 2024
Historique:
received: 18 08 2023
revised: 02 11 2023
accepted: 16 11 2023
medline: 29 11 2023
pubmed: 21 11 2023
entrez: 20 11 2023
Statut: ppublish

Résumé

Obsessive-compulsive and perseverative behaviors (OCBs/PBs) are characteristic features of Huntington's Disease (HD). Although a few recent research have attempted to discriminate between OCBs and PBs, most of the available evidence on OCBs does not consistently make this distinction. In this article, we aimed to explore the current inconsistencies in assessing and reporting OCBs/PBs and map the body of existing evidence. Up to half of the patients with motor manifest HD can experience OCBs. Separate reporting of PBs in HD patients has been uncommon among the studies and was frequently reported as a part of obsessive-compulsive symptoms. The structural limitation of the currently used rating scales and the overlaps in neuropathology and definition of OCBs and PBs are among the main reasons for the mixed reporting of OCBs/PBs. Perseverative thinking or behavior as a separate item is found in a few assessment tools, such as the Problem Behaviors Assessment - Short form (PBA-s). Even when the item exists, it is commonly reported as a composite score in combination with the obsessive-compulsive item. In addition to the significant psychological burden in individuals with HD, PBs are associated with somatic effects (e.g., cardiovascular symptoms) and high-risk behaviors (e.g., suicide). Recognition and monitoring of PBs in HD can aid in early detection of concerning symptoms and differentiating overlapping illnesses.

Identifiants

pubmed: 37984520
pii: S0166-4328(23)00485-0
doi: 10.1016/j.bbr.2023.114767
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114767

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Shayan Abdollah Zadegan (SA)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Huntington's Disease Society of America (HDSA) Center of Excellence at the University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Luke Kupcha (L)

McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Jorge Patino (J)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Huntington's Disease Society of America (HDSA) Center of Excellence at the University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Natalia Pessoa Rocha (NP)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Huntington's Disease Society of America (HDSA) Center of Excellence at the University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. Electronic address: natalia.pessoarocha@uth.tmc.edu.

Antonio L Teixeira (AL)

Huntington's Disease Society of America (HDSA) Center of Excellence at the University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Erin Furr Stimming (E)

Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Huntington's Disease Society of America (HDSA) Center of Excellence at the University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH